arrow
M

Maddalena Barba

National Cancer Institute
H指数:43
被引数:6,814

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study

铂类新辅助化疗及DNA损伤反应生物标志物在TNBC中的预测作用:NeoCarbo研究

2026-05-290
OAAI
Corrigendum to “A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma” [Exp Mol Pathol Volume 146, June 2026, 105049]

勘误:WNT/β-连环蛋白相关转录程序可预测肝癌患者的生存结局 [Exp Mol Pathol Volume 146, June 2026, 105049]

2026-05-280
OAAI
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma

WNT/β-连环蛋白相关转录程序可预测肝细胞癌患者的生存结局

2026-05-110
OAAI
Breast and cervical cancer in transgender men: literature review and a case report

跨性别男性乳腺癌和宫颈癌: 文献回顾和病例报告

2024-08-100
OAAI
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

DARPP-32和t-darpp在anti-HER2药物抗性发展中的作用。STEP研究的临床前证据

2023-11-011
OAAI
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

卡培他滨辅助治疗新辅助治疗后有残留病灶的三阴性乳腺癌患者: 来自CaRe的真实世界证据,一项多中心观察性研究

2023-05-165
OAAI
Sexual dysfunctions in breast cancer patients: evidence in context

乳腺癌患者的性功能障碍: 背景证据

2023-04-188
OA
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
2023-03-0112
OAAI
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Paner研究: 一项来自真实世界环境的HER2-positive晚期乳腺癌患者的多中心观察性研究的20年治疗结果分析

2021-11-296
OAAI
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

基于MicroRNA的签名影响卵巢癌的临床过程和生物学: 一项miRNOmics研究

2021-07-1313
OAAI
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

管腔型乳腺癌中性粒细胞与淋巴细胞比值 (NLR) 的预后相关性: 新辅助治疗的回顾性分析

CELLS
IF5.2
2021-07-0324
OAAI
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

ChangeHER试验中转移性乳腺癌HER2-positivity增益的预后相关性

2021-07-026
OAAI
Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives

口咽和宫颈癌管理中的循环HPV DNA: 当前知识和未来前景

2021-04-0627
OAAI
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives

免疫检查点抑制过程中糖皮质激素使用的姑息和非姑息适应症。当前的证据和未来的前景

2021-01-0111
PREAI
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

三阴性转移性乳腺癌患者的二线Eribulin。多中心回顾性研究: 俄罗斯方块试验

2021-01-017
OAAI